Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,265,936
  • Shares Outstanding, K 83,520
  • Annual Sales, $ 125,670 K
  • Annual Income, $ -126,200 K
  • 36-Month Beta 1.94
  • Price/Sales 42.47
  • Price/Cash Flow N/A
  • Price/Book 10.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.30 +15.88%
on 06/18/18
68.55 -3.14%
on 07/09/18
+7.55 (+12.83%)
since 06/15/18
3-Month
44.60 +48.88%
on 05/10/18
68.55 -3.14%
on 07/09/18
+17.50 (+35.79%)
since 04/17/18
52-Week
33.05 +100.91%
on 08/01/17
68.55 -3.14%
on 07/09/18
+31.40 (+89.71%)
since 07/17/17

Most Recent Stories

More News
29.6% Return Seen to Date on SmarTrend Fibrogen Inc Call (FGEN)

SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on May 15th, 2018 at $50.85. In approximately 2 months, Fibrogen Inc has returned 29.60% as of today's recent price of $65.90.

FGEN : 66.05 (+4.76%)
Watch for Fibrogen Inc to Potentially Pullback After Gaining 2.37% Yesterday

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $62.95 to a high of $65.75. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $63.30...

FGEN : 66.05 (+4.76%)
Shares of FGEN Up 22.1% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on May 15th, 2018 at $50.85. In approximately 2 months, Fibrogen Inc has returned 22.12% as of today's recent price of $62.10.

FGEN : 66.05 (+4.76%)
26.4% Return Seen to Date on SmarTrend Fibrogen Inc Call (FGEN)

SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on May 15th, 2018 at $50.85. In approximately 1 month, Fibrogen Inc has returned 26.35% as of today's recent price of $64.25.

FGEN : 66.05 (+4.76%)
SmarTrend Watching for Potential Pullback in Shares of Fibrogen Inc After 2.02% Gain

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $62.05 to a high of $64.25. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $62.05...

FGEN : 66.05 (+4.76%)
Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

Stock Monitor: EyeGate Pharma Post Earnings Reporting

FGEN : 66.05 (+4.76%)
FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease

FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadustat...

FGEN : 66.05 (+4.76%)
FibroGen to Present at Two Upcoming Investor Conferences

FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that management will participate in a Fireside Chat at the Jefferies 2018 Healthcare Conference in New York, NY on Thursday, June...

FGEN : 66.05 (+4.76%)
FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting

FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced Phase 1/2 clinical trial results of pamrevlumab in combination with standard-of-care chemotherapy in patients with locally advanced...

FGEN : 66.05 (+4.76%)
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018

FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company's randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients...

FGEN : 66.05 (+4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade FGEN with:

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 65.18
1st Resistance Point 64.12
Last Price 66.05
1st Support Level 61.92
2nd Support Level 60.78

See More

52-Week High 68.55
Last Price 66.05
Fibonacci 61.8% 54.99
Fibonacci 50% 50.80
Fibonacci 38.2% 46.61
52-Week Low 33.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar